7 / 7
Page 37
Notes:
conference
series
.com
Volume 8, Issue 5 (Suppl)
J Biom Biostat, an open access journal
ISSN: 2155-6180
Biostatisitcs 2017
November 13-14, 2017
November 13-14, 2017 | Atlanta, USA
6
th
International Conference on
Biostatistics and Bioinformatics
Unbiased estimation after phase II clinical trials involving multiple endpoints
T
he single arm, two-stage clinical trial design is a popular methodology to evaluate oncology treatments in the phase II
setting. The designs are typically augmented with an ad hoc toxicity monitoring rule which is imposed outside of the
formal two-stage design but there are also several designs that formally incorporate both endpoints simultaneously. There are
many problems that prevent the designs from being used in practice which includes point estimation after the execution of
the study. We will examine an unbiased estimator that accounts for both endpoints simultaneously along with the correlation
between the endpoints. The behavior of the estimate is examined through simulation studies. It is compared to the maximum
likelihood estimator.
Biography
Herman Ray has received his PhD from the University of Louisville, where he has conducted research at the JG Brown Cancer Center. He currently has several
manuscripts published in clinical trial design and bioinformatics as well as STEM education policy in the secondary education system. He is now an Associate
Professor of Statistics at Kennesaw State University as well as the Director of the Center for Statistics and Analytical Research which is housed within the new
Analytics and Data Science Institute.
hray8@kennesaw.eduHerman Ray
Kennesaw State University, USA
Herman Ray, J Biom Biostat 2017, 8:5 (Suppl)
DOI: 10.4172/2155-6180-C1-004